Efinaconazole
Efinaconazole is a triazole antifungal medication primarily used in the treatment of nail infections caused by fungi, specifically for the treatment of onychomycosis, a fungal infection that affects the toenails or fingernails. Efinaconazole acts by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes, thereby exerting its antifungal effects and leading to the death of the fungal cells.
Medical Uses[edit | edit source]
Efinaconazole is indicated for the topical treatment of onychomycosis of the toenails or fingernails due to dermatophytes (Trichophyton rubrum and Trichophyton mentagrophytes) and/or yeast (Candida species). Its formulation as a 10% topical solution is designed to penetrate the hard keratin of the nail, reaching the site of infection and providing effective antifungal activity.
Pharmacology[edit | edit source]
Mechanism of Action[edit | edit source]
Efinaconazole inhibits the synthesis of ergosterol by inhibiting fungal enzymes, specifically 14α-demethylase. This enzyme is involved in the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. The inhibition of ergosterol synthesis leads to an accumulation of toxic intermediate products in the cell membrane and results in increased membrane permeability and ultimately, the death of the fungal cell.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of efinaconazole shows that when applied topically, systemic absorption is minimal. This characteristic minimizes systemic side effects and makes efinaconazole a safe option for the treatment of onychomycosis. The drug is primarily metabolized in the liver and excreted in the feces.
Adverse Effects[edit | edit source]
The most common adverse effects associated with efinaconazole are local reactions at the application site, such as dermatitis, erythema, irritation, and pain. These reactions are generally mild and transient. Systemic side effects are rare due to minimal systemic absorption.
Contraindications[edit | edit source]
Efinaconazole is contraindicated in patients with known hypersensitivity to efinaconazole or any of the excipients in the formulation. Caution is advised when prescribing to pregnant or breastfeeding women due to the lack of sufficient safety data.
Interactions[edit | edit source]
Given its minimal systemic absorption, efinaconazole has a low potential for drug-drug interactions. However, patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements, to assess for potential interactions.
Administration and Dosage[edit | edit source]
Efinaconazole is applied topically to the affected nail(s) once daily. The treatment duration is typically 48 weeks, but the duration may vary based on the severity of the infection and the clinical response. It is important to follow the application instructions carefully to ensure the medication reaches the site of infection effectively.
Conclusion[edit | edit source]
Efinaconazole is an effective and safe option for the topical treatment of onychomycosis. Its mechanism of action, targeting the synthesis of ergosterol, makes it a potent antifungal agent against the fungi responsible for nail infections. While efinaconazole is generally well-tolerated, patients should be aware of potential local adverse effects and follow their healthcare provider's instructions for use.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD